XFOR Gains FDA Orphan Drug Designation for Mavorixafor, Market Pricing Reflects Growth Expectations
· gurufocus.com
On August 26, 2026, X4 Pharmaceuticals Inc (NASDAQ: XFOR) announced that its experimental drug mavorixafor received orphan drug designation from the U.S. Food a
On August 26, 2026, X4 Pharmaceuticals Inc (NASDAQ: XFOR) announced that its experimental drug mavorixafor received orphan drug designation from the U.S. Food a...